Indian biotech firm develops world’s first, indigenous Bi-Specific 3rd generation CAR T cells for cancer treatment

Indian biotech firm pioneers CAR-T cell therapy for cancer treatment

Cellogen Therapeutics secures patent for India’s first Bi-Specific CAR T Cell therapy

Cellogen Therapeutics awaits CDSCO nod for human trial on its ‘bi-specific 3rd generation’ CAR-T therapy

Cellogen Therapeutics secures patent for its cell therapy for blood cancer

Cellogen Therapeutics gets DCGI nod to develop indigenous Bi-Specific 3rd Generation CAR T cells for cancer

Cellogen Therapeutics secures patent for world's first bi-specific CAR T

How India can better its clinical trials for cell and gene therapy

Natco Pharma to acquire 5% stake in biotech startup Cellogen Therapeutics for ₹15 cr.

NATCO Pharma Limited invests around US$ 2 million in Cellogen Therapeutics

Natco Pharma invests $2 million in Cellogen Therapeutics

World Sickle Cell Awareness Day: Can gene therapy be the silver bullet? An Indian start-up looks for a breakthrough

Natco pharma picks up 5.38% stake in cell & gene therapy startup Cellogen Therapeutics

Natco Pharma to acquire 5% stake in biotech startup Cellogen Therapeutics for ₹15 cr.

Cellogen to bring next-gen cancer therapy to India

How India can accelerate in genetic research

How innovations in CAR T-Cell therapy pave way for broader and safer cancer treatment

OPINION | CAR T-cell therapy is proving to be promising in the treatment of solid tumours

Rewriting our DNA: The potential of gene editing for blood disorders and beyond

How cell and gene therapies revolutionising cancer care in India